Cardio-oncology
Review | Interventional cardio-oncology: unique challenges and considerations in a high-risk population
8 Aug, 2023 | 13:27h | UTC
Review | Guiding the use of invasive cardiac interventions in patients with advanced malignancies
17 Jul, 2023 | 13:23h | UTC
Review | How to treat diffuse large B-cell lymphoma: oncologic and cardiovascular considerations
26 Jun, 2023 | 00:33h | UTC
Commentary on Twitter
Are you struggling w/ how to protect patients w/ #DLBCL & CV comorbidities from #anthracycline #cardiotoxicity?
Follow this simple "how to guide" to cardioprotection by Dr. @SwethaKamMD et al in #JACCCardioOnc: https://t.co/d07eqOcB6V#lymphoma #CardioOnc #lymsm #CardioTwitter pic.twitter.com/W33FHjwA63
— JACC Journals (@JACCJournals) June 22, 2023
Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies
1 Jun, 2023 | 11:48h | UTC
RCT | Statins do not prevent early cardiac dysfunction in anthracycline-treated cancer patients
15 May, 2023 | 13:07h | UTCStatins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines – European Heart Journal – Cardiovascular Pharmacotherapy (link to abstract – $ for full-text)
Commentary on Twitter
Primary prevention with atorvastatin during anthracycline therapy did not prevent cardiac dysfunction and myocardial tissue changes: SPARE-HF randomized trial https://t.co/9s2p9JSSq4 #echofirst #HF #LVEF #CMR #ESCYoung #EHJPharmacotherapy @FeliceGragnano @AgewallStefan pic.twitter.com/7tKG4tdpcD
— European Society of Cardiology Journals (@ESC_Journals) May 13, 2023
Cohort Study | Outcomes of surgery in cardiac angiosarcoma
12 May, 2023 | 13:35h | UTC
Commentary on Twitter
A study in #JACCCardioOnc from US national cancer database identifies 239 patients w/ rare cardiac tumor angiosarcoma:
🔸 Surgery is underutilized
🔸 Higher income, recentness of Dx, early stage, use of surgery, & #chemotherapy had a better outcome— JACC Journals (@JACCJournals) May 6, 2023
Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials
10 May, 2023 | 15:54h | UTCEditorials:
Atrial Fibrillation With Modern Cancer Treatment: More Common Than We Think – JACC: CardioOncology
Commentary on Twitter
Annual incidence rate of #AFib assoc w/ anticancer drugs were ⬆️ in pts w/ hematologic malig. It was found for #ibrutinib 4.92 (95% CI: 2.91-8.31), #clofarabine 2.38 (95% CI: 0.66-8.55), & #ponatinib 2.35 (95% CI: 1.78-3.12) per 100 person-yrs https://t.co/W2RGMrE37F… pic.twitter.com/NnbmUVcci5
— JACC Journals (@JACCJournals) April 27, 2023
RCT | Ibrutinib plus rituximab improve CLL PFS vs chemoimmunotherapy, but increased unexplained/cardiac deaths
8 May, 2023 | 13:00h | UTC
Cohort Study | Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients
8 May, 2023 | 12:59h | UTC
Commentary on Twitter
#Ibrutinib was associated with an increased risk of stroke, #AFib and bleeding, especially in older patients. The risk of major bleeding is higher than previously reported. https://t.co/dhP7Kwogdt#JACCCardioOnc #CardioOnc #geriheme #lymsm #leusm #CLL @AkivaDiamond @paolocaimiMD pic.twitter.com/MvzCh1i6LU
— JACC Journals (@JACCJournals) May 4, 2023
Review | Cancer treatment-related cardiovascular toxicity in gynecologic malignancies
26 Apr, 2023 | 14:14h | UTC
Commentary on Twitter
A comprehensive #JACCCardioOnc state-of-the-art review of cancer treatment-related cardiovascular toxicity in gynecologic malignancies: https://t.co/24sFcHfyPf#GynOnc #GynCSM #CardioOnc #cardiotoxicity #CardioTwitter @emorywomenheart @sdent_duke pic.twitter.com/kzqILRzuwz
— JACC Journals (@JACCJournals) April 20, 2023
Cohort Study | Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer
26 Apr, 2023 | 14:05h | UTCNews Release: Previous cancer linked to long term heightened risk of CVD – BMJ Newsroom
Cardiovascular disease in testicular cancer survivors: Identification of risk factors and impact on quality of life
25 Apr, 2023 | 14:34h | UTC
Cohort Study | Risk of cancer after diagnosis of cardiovascular disease
25 Apr, 2023 | 14:29h | UTCRisk of Cancer After Diagnosis of Cardiovascular Disease – CardioOncology
Commentary: New details on the link between CVD and cancer, from a study of 27M patients – Cardiovascular Business
Outcomes of ST elevation myocardial infarction in patients with cancer: a nationwide study
27 Mar, 2023 | 13:12h | UTCOutcomes of ST elevation myocardial infarction in patients with cancer: a nationwide study – European Heart Journal – Quality of Care and Clinical Outcomes (free for a limited period)
Commentary on Twitter
Cancer and #STEMI – a worrisome combination of higher short- and long-term mortality, and bleeding risk. https://t.co/kHvhGP0PBE #EHJQCCO #cardiotwitter @cpgale3 @diogoasantosfer pic.twitter.com/SfjyizoJvQ
— European Society of Cardiology Journals (@ESC_Journals) March 26, 2023
Retrospective Cohort | Arrhythmogenic cardiotoxicity associated with contemporary treatments of lymphoproliferative disorders
14 Mar, 2023 | 13:27h | UTC
Cardiovascular disease related to immune therapy: JACC: CardioOncology special focus issue
28 Feb, 2023 | 13:37h | UTCCardiovascular Disease Related to Immune Therapy: JACC: CardioOncology Special Focus Issue – JACC: CardioOncology
Homepage: Special Focus Issue: Immune Therapy
Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review
Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer
Related:
Cardiovascular complications of immune checkpoint inhibitors for cancer – European Heart Journal
Cardiotoxicity of immune checkpoint inhibitors – ESMO Open
Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature
Case-control study | Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010
6 Feb, 2023 | 13:20h | UTCInvited Commentary: Heart Failure in Patients With Cancer Treated With Anthracyclines—Revisiting the Foundation of Cardio-Oncology- JAMA Network Open
Commentary on Twitter
Anthracycline is linked to double the rate of heart failure in patients with cancer vs matched controls, 7.4% at 15 years. https://t.co/SxlJkJ7oLR
— JAMA Network Open (@JAMANetworkOpen) February 3, 2023
Consensus Paper | Cardio-oncology recommendations for pediatric oncology patients
31 Jan, 2023 | 13:54h | UTC
Pre-existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy
26 Jan, 2023 | 12:09h | UTC
Cohort Study | Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor–induced myocarditis
24 Jan, 2023 | 14:16h | UTCCommentary: Biomarker Trends of Immune Checkpoint Inhibitor–Induced Myocarditis – American College of Cardiology
Commentary from the author on Twitter
Our work is now published in @JACCJournals!
ICI #myocarditis rarely occurs in isolation. Elevations in routinely measured biomarkers should prompt further testing for cardiac injury🫀 @salimhayek @umichCVC @UMRogelCancer
Check it out👇https://t.co/6o8k4Pbp8J pic.twitter.com/cJzgpqPkL0
— Alexi Vasbinder, PhD, RN (@Avasbind) December 20, 2022
AHA Statement | Cancer therapy-related hypertension
23 Jan, 2023 | 13:46h | UTCTop Things to Know: Cancer Therapy-Related HTN – American Heart Association
The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology
9 Jan, 2023 | 14:08h | UTC
Commentary on Twitter
The Year in Cardiovascular Medicine 2022 series: the Top 10 papers in Cardio-oncology https://t.co/hfWJ94MmxK@escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes @mayocvonc #cardioonco #CVD @TeresaLpezFdez1 pic.twitter.com/30SNvdvkEV
— European Society of Cardiology Journals (@ESC_Journals) January 2, 2023
Consensus Paper | Evaluation and management of cancer patients presenting with acute cardiovascular diseases.
9 Dec, 2022 | 13:28h | UTCRelated:
The ‘Ten Commandments’ for the 2022 European Society of Cardiology guidelines on cardio-oncology.
#ESCCongress | 2022 ESC Guidelines on cardio-oncology.
Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia
Review | AL Amyloidosis for Cardiologists.
6 Dec, 2022 | 13:36h | UTC
The ‘Ten Commandments’ for the 2022 European Society of Cardiology guidelines on cardio-oncology.
29 Nov, 2022 | 14:13h | UTCOriginal guideline: #ESCCongress | 2022 ESC Guidelines on cardio-oncology.